Melane Sampson, Author at BioTuesdays

Developments

AIM signs Phase 3 design deal for Ampligen in pancreatic cancer

AIM ImmunoTech (NYSE American: AIM) has announced the signing of an agreement with Thermo Fisher Scientific’s (NYSE: TMO) PPD clinical research business to design its Phase 3 clinical trial for Ampligen in the treatment...

March 2, 2026

Executive Moves

Prof. Joshua C. Brown joins NRx as CMO

NRx Pharmaceuticals (NASDAQ: NRXP) has announced the appointment of Prof. Joshua C. Brown, MD, PhD, as chief medical officer. Prof. Brown, a pioneer in understanding the biologic effect of Transcranial Magnetic...

March 2, 2026

Developments

Zomedica expands distribution with Moichor partnership

Zomedica (OTCQB: ZOMDF) has entered into a commercial distribution agreement with closely held Moichor, a veterinary reference and point-of-care laboratory service, to expand its distribution of TRUVIEW(R) digital...

February 25, 2026

Developments

Tiziana announces positive new biomarkers for nasal foralumab

Tiziana Life Sciences (NASDAQ: TLSA) has announced new biomarker data from a late-breaking poster presented by investigators from Brigham and Women’s Hospital, Boston, showing nasal foralumab downregulates cerebrospinal...

February 25, 2026

Feature

MediWound healing without surgery through a pineapple-derived enzymatic approach

MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...

February 24, 2026

Executive Moves

Foghorn appoints Ryan Maynard as CFO

Foghorn Therapeutics (NASDAQ: FHTX) has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. Mr. Maynard brings more than 25 years of executive experience driving financial...

February 23, 2026

Developments

FDA grants QIDP for Armata’s AP-SA02

Armata Pharmaceuticals (NYSE American: ARMP) has announced that the FDA has granted AP-SA02 Qualified Infectious Disease Product (QIDP) designation for intravenous use in the adjunct treatment of complicated bacteremia...

February 23, 2026

Executive Moves

Drs. Mark Eisner and Ajay Nirula join Zura Bio’s BOD

Zura Bio (NASDAQ: ZURA) has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the...

February 23, 2026

Developments

C4 doses first patient in Phase 2 trial of cemsidomide in RRMM

C4 Therapeutics (NASDAQ: CCCC) has announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple...

February 23, 2026

Developments

Acrivon launches internal CLIA-certified lab

Acrivon Therapeutics (NASDAQ: ACRV) has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in...

February 18, 2026

Author - Melane Sampson

AIM signs Phase 3 design deal for Ampligen in pancreatic cancer

Prof. Joshua C. Brown joins NRx as CMO

Zomedica expands distribution with Moichor partnership

Tiziana announces positive new biomarkers for nasal foralumab

MediWound healing without surgery through a pineapple-derived enzymatic approach

Foghorn appoints Ryan Maynard as CFO

FDA grants QIDP for Armata’s AP-SA02

Drs. Mark Eisner and Ajay Nirula join Zura Bio’s BOD

C4 doses first patient in Phase 2 trial of cemsidomide in RRMM

Acrivon launches internal CLIA-certified lab

Subscribe